Given the fact that amorphous solid dispersions (ASD) have been one of the most popular formulation strategies to address the issue of inadequate aqueous solubility for small molecules, it is of particular interest to control crystal growth from supersaturated solution in order to maximize the extent of oral absorption of therapeutic agents. Recently, bile salts have been shown to delay crystallization of poorly soluble compounds. In this study, an in-situ common history seeding method was proposed to provide seeds that better mimic crystals formed from supersaturated solutions. The effectiveness of both monomeric and miceller biorelevent bile salts on solution crystal growth and secondary nucleation of telaprevir was then examined. Most bile salts investigated in this study exhibit growth inhibition properties. The extent of growth inhibition, however, various with structural difference amongst the bile salts and their aggregation level.
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INTRODUCTION
Controlled crystallization with additives has been of great interests to the pharmaceutical industry. Due to the increased number of poorly soluble compound in the drug developmental pipeline, contemporary formulation strategies often involve implementing a higher energy form of active pharmaceutical ingredients (APIs). Take amorphous solid dispersion for example, the amorphous solids and the dissolved solution improve the extent of oral absorption by providing drug transport with a higher concentration gradient across the membrane.
1-3 However, the inhered crystallization tendency of these high energy forms of API often imperils the stability and performance of the formulations. 4 Employing foreign components to interrupt the crystallization process thus become an answer to maintaining solubility advantages of these formulations.
5
Solution crystallization consists of two major kinetic events: nucleation and crystal growth. Nucleation take place when a supersaturated system overcomes the free energy barrier for critical nucleus formation 6 , following by a consumption of molecularly dissolved solute due to new crystalline matter formation. Current research mostly focus on the impact of additives on nucleation. For instance, polymers are well known nucleation inhibitors for APIs, 7-10 while surfactants on the other hands are found to promote nucleation 11 . Besides the commonly employed excipients in commercial formulation, bile salts, the endogenous surfactant exist in human intestinal fluids, has been shown to inhibit nucleation of a wide variety of structurally Figure 1 and Table   1 . A regenerated cellulose membrane with a molecular weight cutoff (MWCO) of 6-8k Da was acquired from Spectrum Laboratories, Inc. (Rancho Dominguez, CA). The aqueous media used in all experiments was 50mM pH 6.5 sodium phosphate buffer.
METHODS

In-situ Common History Seeding and Mass Growth Rate Measurements.
Crystal growth is sensitive to seed properties. To better mimic how nuclei grow when they first form in supersaturated solution, an in-situ common history seeding method was implemented to provide suitable seeds for telaprevir crystal growth rate measurements (Figure 2 ).
Supersaturated telaprevir solutions were prepared by titrating concentrated methanolic telaprevir stock solution (12 mg/mL) to 50mL of 50 mM pH 6.5 sodium phosphate buffer to achieved telaprevir concentration of 60µg/mL. The supersaturated solution was then stirred at 300 rpm at 37 ¡C for 6 hours to allow crystallization taking place. After fixed 6 hour seeding period, telaprevir solution concentration was observed to decrease back to it crystalline solubility, and supersaturation in solution was regenerated by adding methanolic telaprevir stock solution according to the activity-based supersaturation calibration curves shown in our previous study[cite manuscript#2] to achieve different initial supersaturation levels. The corresponding concentrations are listed in 
Residual Supersaturation Determination.
A side-by-side diffusion cell (PermeGear, Inc. Hellertown, PA) was used to evaluate the residual supersaturation level of telaprevir crystallized solutions in the absence and presence of different bile salts (at 1.86 mM or 12 mM bile salt concentrations). The basic concepts were as described in the previous studies.[cite M#1 and M#2] The ratio of solute mass flow rate in the solution of interest (F) to the mass flow rate of the corresponding standard state system (F¡), solute in a solution in equilibrium with crystalline state in this study, yields the fundamental supersaturation δ:
where ! is the solute activity in the solution of interest, and !! is the solute activity at standard state. With the mass flow rate data and the previously established calibration curve[cite manuscript#1], residual supersaturation level of telaprevir solution after 15 hour growth can be determined from Equation (1).
Seed Crystal Morphology Characterization.
The scanning electron microscopy (SEM) was used to reveal the morphology of telaprevir crystals prepared by the in-situ common history seeding method as well as the ones obtained from suppliers. For telaprevir crystals prepared by in-situ common history seeding method, small amount of liquid samples (approximately 10µL) were extracted from the seeded solution after 6 hour seeding time, and deposit on glass coverslips and placed into the vacuum oven for a week prior to observation to remove any remaining liquid. The dried samples were sputter-coated with platinum for 60 seconds, and imaged with a FEI NOVA nanoSEM field emission SEM (Hillsboro, Oregon), using an Everhart−Thornley detector (ETD) and through-the-lens detector (TLD). The parameters were 5 kV accelerating voltage, about 5 mm working distance, beam spot size of 3, 30 µm aperture, and magnifications in the 5000−30000× range.
Zeta Potential Measurements.
The zeta potentials of telaprevir seed crystals in solutions in the presence of monomeric bile salts were measured using a Nano-Zetasizer (Nano ZS, Malvern, Westborough, MA). Telaprevir seed crystals were obtained by titrating concentrated methanolic telaprevir stock solution (12 mg/mL) into 10mL of 50 mM pH 6.5 sodium phosphate buffer with 1.86mM bile salts. The solutions were stirred at 300rpm at 37¡C, allowing crystallization to take place, and the seed crystals were continuously stirred overnight for equilibrium. 1.86mM of bile salts were added to the stirred seed crystal solution 30 minutes prior to zeta potential measurements. The zeta potentials of telaprevir seed crystals with no bile salt were also measured for reference.
RESULTS AND DISCUSSIONS
Common History Seed Crystals and Crystal Growth rates
Seeding has been a crucial step to crystallization in the pharmaceutical industry as it strongly dictates the final product properties. It has been demonstrated that seed crystals prepared in different environments leads to different abilities to subsequently grow 23 . To prepared seeds that better imitate crystal growth after direct nucleation from supersaturated solutions, we
proposed an in-situ common history seeding methods. The concept of common history seed was first introduced by White et al., in which the authors described common history (CH) seed as a batch of crystal that were nucleated at the same time and then experience the same growth history, i.e. under same temperature, same supersaturation and for the same length of time. 25 For CH seed, it is reported that the shape of the crystal size distribution will be maintained throughout the crystallization process and as these seed crystal grows. 26, 27 In this study, all seeds crystals were prepared by direct nucleation from telaprevir supersaturated solutions, with an initial concentration of 60µg/mL, at 37¡C for 6 hours. After the fixed seeding period, telaprevir solution concentrations were observed to be around telaprevir crystalline solubility. That is, same seed loading (mass-wise) were provided with our proposed seeding method. Figure 3 shows the desupersaturation profile of telaprevir crystals in the absence of bile salts after supersaturation was regenerated. The desupersaturation rate under three different supersaturation levels is 5.4±0.8µg/min, 58.6±2.2µg/min and 89.2±7.6µg/min, respectively. The high reproducibility of the desupersaturation curves imply our good control over seed properties with the proposed method. The impact of preparation methods on seed properties is revealed in Figure 4 . It should be noted that control experiment (in-situ seeding in water) was shown as well to confirm that the observed crystals were not from buffer salts. It is evident that the primary particle size of crystal obtained from supplier is larger than the ones prepared by the in-situ CH seeding method and the shape are different, which can potentially affect crystal growth behavior. In addition, we observed that telaprevir seeds prepared by the insitu CH method tend to form bouquet-like aggregates, which is difficult to evaluate crystal growth rates by performing image analysis for individual crystals. Therefore, crystal growth rates in this study were determined by the monitoring the change in solution concentration, which is directly related to the mass deposition on existing seed crystals.
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Amongst the three supersaturation levels performed in this study, there was no observable change in turbidity measurement for experiments with initial supersaturation level δ=2.4. That is, there was no evidence of significant secondary nucleation for these systems, and the desupersaturation can be assumed to be mainly due to the bulk crystal growth of the seed crystals. On the other hand, there were detectable increase in turbidity measurements for experiments at higher supersaturation levels (δ=7.9 and 12.5), indicating the occurrence of secondary nucleation. Therefore, crystal growth rates in this study were determined from the desupersaturation rates at supersaturation level δ=2.4. The desupersaturation rates at higher supersaturation levels were as well investigated to evaluate the impact of bile salts on secondary nucleation kinetics.
Crystal Growth and Desupersaturation Rates of Telaprevir in the Presence of Bile Salts
The impact of bile salts on telaprevir desupersaturation rate was investigated at three different initial supersaturation ratio. At supersaturation level δ=2.4, where crystal growth being the dominating kinetics, the effectiveness of bile salts in inhibiting crystal growth E G was estimated using the following equation:
where R 0 and R are the initial desupersaturation rate in the absence and presence of bile salt, respectively. Bile salts with E G >1 were considered to be effective crystal growth inhibitors. At higher supersaturation levels δ=7.9 and 12.5, where both crystal growth and secondary nucleation can take place, the effectiveness of bile salts in inhibiting the combined kinetics E c was then estimated using the Equation (3). Bile salts with E C >1 were considered to be effective inhibitors for the combined kinetics. To investigate the potential impact of monomeric bile salts on telaprevir secondary nucleation kinetics, the desupersaturation rate raito as a function of supersaturation is shown in Figure 7 . For solutions with 1.86mM STC, the desupersaturation rate ratio increased with increasing supersaturation level. Meanwhile, desupersaturation was completely inhibited in the presence of monomeric STCDC at all supersaturation levels. These observations serve as evidence that monomeric STC and STCDC slow down telaprevir crystallization kinetics even when secondary nucleation takes place. This supposition is further supported by comparing the turbidity measurements at different supersaturation levels. While there appeared to be detectable secondary nucleation based on turbidity measurements for solutions in the absence of bile salts at higher supersaturation level (δ=7.9 and 12.5), there was no evidence for secondary nucleation for solutions in the presence of monomeric STC and STCDC. That is, these two bile salts appear to inhibit telaprevir secondary nucleation at 1.86mM concentration.
Zeta potential measurements, an indication of electric potential difference at interfaces in solution, were conducted to understand the interactions of monomeric bile salts and the telaprevir crystals. In the literature, it is well known that adsorption (both physically and chemically) of ionized species can changes the measured zeta potential. 32 33 Telaprevir is neutral, and monomeric bile salt is negatively charged in the buffer medium used in this study. Therefore, the change in zeta potential upon addition of monomeric bile salt serves as a qualitative indication of adsorption of bile salts at the telaprevir crystal interface. With bulk crystal growth rate measurements and population balance modeling, Abbou Oucherif 35 showed that the growth mechanism of dipyridamole shifted from being mass transfer controlled to being a hybrid between mass transfer and surface integration controlled in the presence of 2.2mM STC. More detailed studies are indeed required to fully explain the inhibition mechanism of bile salts.
In order to further confirm the inhibition ability of bile salts, residual supersaturation of the telaprevir solutions (δ=12.5) after 15 hour of crystallization was determined. By comparing Table 3 and Figure 5 , the residual supersaturaiton is directly related to the effectiveness of bile salts (E C ). With STC being the medium crystallization inhibitor, the majority of the initial provided supersaturation was consumed after 15 hours of crystallization. On the other hand, STCDC at 1.86mM concentration was able to maintain the supersaturation over 15 hours, while similar effect was not observed when bile salt concentration increased to 12mM. This observation further support our previous statement that monomeric STCDC is a highly effective inhibitor, for both crystal growth and secondary nucleation, for telaprevir. Since possible complexation can be form between SGCDC and telaprevir,[cite M#1] residual supersaturation was used to evaluate the effectiveness of SGCDC instead of using the desupersaturation method.
As shown in Table 3 , SGCDC shows similar behavior to STCDC. At 1.86mM SGCDC concentration, supersaturation was maintained over 15 hours. However, similar inhibition effect was not observed as SGCDC concentration increased to 12mM. By summarizing the observations, it is evident that monomeric STCDC and SGCDC are highly effective inhibitor for telaprevir crystal growth and secondary nucleation inhibitors. In addition, micelles of STCDC and SGCDC appear to negate the inhibitory impact of the monomers.
Nucleation Inhibition Versus Growth Inhibition
For system with additives, it is feasible to decouple the crystal growth effect from the measured nucleation induction time with proper experimental design and hence have a better understanding of nucleation kinetics. 28, 36 In the previous study, we showed that unseeded supersaturated telaprevir solutions can be maintain to different extent in the presence of bile salts.
However, we revealed that bile salts show different impact on crystal growth rates in the current study. That is, it is possible that the observed prolonged induction time was contributed by strong crystal growth inhibition. With the determining seedless induction times from the previous study[cite M#2] and the seeded desupersautration rates in the presence and absence of bile salts ( Figure 5(b) ) under similar experimental conditions, the relative nucleation rate in the presence and absence of the bile salt is estimated with the following equation:
where J is the nucleation rate in the presence of bile salts, J 0 is the nucleation rate in the absence of bile salts, R 0 /R is the desupersautration rate in the absence of bile salts divided by the rate in the presence of bile salts, t u,0 is the unseeded induction time in the absence of bile salts and t u is the induction time in the presence of bile salts. The effectiveness of bile salts in inhibiting nucleation E J was further defined as below, and bile salts with E J >1 were considered to be effective nucleation inhibitors.
For example, the induction time in the absence of bile salts was determined to be ~30 minutes and in the presence of monomeric bile salts the induction time was found to be more than 16 hours (960 minutes was used in the calculation).[cite M#2] With the desupersautration rate ratios from Figure 5 (b), E J for monomeric bile salt, except STCDC and SGCDC, was then estimated to be around the range of 400-340,000, much higher than the estimated values of E G (ranging between 1-3). That is to say, the ability of monomeric STC, SGC, STDC and SGDC to maintain supersaturation via growth inhibition is much weaker compared to their ability to inhibit nucleation. As for the extreme effective growth inhibitor, monomeric STCDC and SGCDC, there was no desupersautration observed during the experiments. By assuming E G to be 100, the E J value estimated with Equation (4) and (5) is minimal, indicating that the prolonged induction time we observed in the previous study can be due the strong growth inhibition by STCDC and SGCDC. In other words, it is possible that nucleation did take place, but the nuclei were not able to grow to a detectable size due to monomeric STCDC and SGCDC blocking crystal growth. It was reported in a previous nucleation induction time study that monomeric STCDC possesses the highest inhibitory effect for the three poorly soluble compounds, celecoxib, nevirapine, and flibanserin, compared to other 12 different bile salts. 13 Based on our observations, growth inhibition can be a possible contributing factor.
Similar analysis was performed for bile salts at 12 mM, and Figure 8 summarized the inhibition ability of biorelevant bile salts at different aggregation levels. In general, we can categorize bile salts with some structural dependence. For trihydroxy bile salt STC and SGC, they exhibit strong ability in inhibiting telaprevir nucleation. As bile salt concentration increased to 12mM, the presence of micellar bile salts does not appeared to show significant impact on the inhibition ability (Figure 8(a) ). For STDC and SGDC, dihydroxy bile salt with the absence of hydroxyl group at R 3 position on the steroid ring system, these bile salts appeared to be strong nucleation inhibitors for telaprevir at monomeric form. However, micelles of these dihydroxy bile salts appears to negate the inhibitory impact of the monomers (Figure 8(b) ), which is consistent to our observation in the previous study.[cite M#2] For STCDC (and SGCDC), dihydroxy bile salt with the absence of hydroxyl group at R 4 position on the steroid ring system, the monomeric form show extreme effectiveness in inhibiting telaprevir crystal growth. Similar to other dihydroxy bile salts, micelles of these dihydroxy bile salts appears to negate the inhibitory impact of the monomers (Figure 8(c) ).
Importance of Bile Salt Inhibition Properties.
Due to the inevitable encounter of oral formulations with bile salts in biorelevant dissolution media and in vivo, understand the impact of bile salts on API crystallization has been a new area of research interest. For amorphous formulations, maintaining supersaturation for a biologically relevant time frame in the gastrointestinal tract is important for improved absorption.
Although the composition varies from person to person, the bile salts investigated in this study are commonly found in human intestinal fluids. 37, 38 It was demonstrated in the previous studies that bile salt significantly delayed crystallization of poorly soluble compounds from solution.
12, 13 [cite M#2] However, their impact on crystal growth rate has not been considered. The presence of residual (seed) crystals is often unavoidable in an amorphous formulation due to its instable nature. The ability to control or slow down crystal growth significantly impact the degree of supersaturation available for absorption. Take telaprevir for example, supersaturation is possible to be maintained upon exposure in vivo, even with residual crystallinity present in the ASD, due to the crystal growth inhibition of the biorelevant bile salts. For polymer systems, it was reported that the extent of crystal growth inhibition can be improved through surface poisoning upon seed preparation. 23 If similar mechanism applied, larger impact of bile salts on drug crystallization is expected if bile salts are employed as excipient in amorphous formulations.
CONCLUSIONS
In this study, the impact of six biologically relevant bile salts on desupersautration rate of seeded telaprevir solutions was evaluated at different bile salt aggregation levels. With the proposed in-situ common history seeding method, differences in the inhibitory ability of the bile salts were revealed. Most bile salts investigated slowed down telaprevir crystal growth.
Monomeric STCDC and SGCDC were extremely effective growth inhibitors for telaprevir, and solution supersaturation was able to be maintained over time. However, the presence of the bile salt micelles opposed their monomeric inhibitory effect. In addition, Monomeric STC and STCDC were found to inhibit secondary nucleation of telaprevir at higher supersaturation levels.
These observations of the endogenous bile salts provide the foundation for further studies on how biorelevant bile salt mixture impact the crystallization kinetics of drugs, which are crucial for better biopredictive dissolution media design and better in vivo behavior prediction of supersaturating systems. Lastly, bile salts are not interchangeable from a crystallization inhibition standpoint. 
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